Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions View by Topic View by Date Must Reads In Genitourinary Cancer Genitourinary Cancer for November/December 2020 Study shows no link between race and mortality in clear cell RCC, Four factors may predict better survival with cabozantinib in mRCC, Focal radiation boost nets better outcomes in prostate cancer, Fear of recurrence highly prevalent in RCC survivors, Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest, More must reads Genitourinary Cancer for September/October 2020 PET guidance for radiation therapy improves prostate cancer outcomes, Single and multifraction SBRT found comparable for lung metastases, ‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients, Novel assay may better detect urothelial carcinoma, Durable efficacy with MK-6482 in VHL-associated RCC, More must readsGenitourinary Cancer for July/August 2020 VTE, sepsis risk increased among COVID-19 patients with cancer, Study links gut microbiome and mRCC treatment outcomes, Aspirin may accelerate cancer progression in older adults, Immune checkpoint inhibitors don’t increase risk of death in cancer patients with COVID-19, How prostate cancer treatments affect quality of life, More must readsGenitourinary Cancer for May/June 2020 Personalized cancer vaccine may enhance checkpoint inhibitor activity, Oral relugolix works to a T against advanced prostate cancer, Video coaching may relieve anxiety and distress for long-distance cancer caregivers, COVID-19 death rate was twice as high in cancer patients in NYC study, Antitumor treatment may increase risk of severe events in COVID-19 patients, More must readsGenitourinary Cancer for March/April 2020 Cancer prevalence among COVID-19 patients may be higher than previously reported, Genomic prostate score does not improve risk assessment, Lymphopenia linked to worse response in RCC, bladder cancer patients on checkpoint inhibitors, Antidepressant could treat recurrent prostate cancer, HRQOL deteriorates after disease progression in metastatic cancer, More must readsPages1 2 3 4 5 6 last »
